Oncoinvent ASA
Research Oncoinvent ASA (ONCIN) on Bullrun: market cap NOK 380.67M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerONCIN
- ExchangeOL
- CountryNorway
- SectorHealthcare
- IndustryBiotechnology
- CurrencyNOK
- Market capNOK 380.67M
- Financial periodFY2025
- RevenueNOK 28.07M
- Revenue growth246.5%
- Net income-NOK 155.07M
- Free cash flow-NOK 129.99M
- Gross margin100.0%
Valuation Snapshot
latest market cap is NOK 380.67M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | NOK 28.07M | -NOK 155.07M | -NOK 129.99M | 100.0% | -1.25 | NOK 177.60M | NOK 3.55M | NOK 146.32M |
| FY2024 | NOK 8.10M | -NOK 140.20M | -NOK 89.75M | 100.0% | -5.61 | NOK 133.67M | NOK 7.45M | NOK 108.33M |
| FY2023 | NOK 5.79M | -NOK 143.62M | -NOK 164.94M | 100.0% | -738.62 | NOK 30.10M | NOK 12.17M | NOK 54.93M |
| FY2022 | NOK 6.28M | -NOK 106.28M | -NOK 93.17M | 100.0% | -548.04 | NOK 196.02M | NOK 12.03M | NOK 193.82M |
| FY2021 | NOK 11.08M | -NOK 80.29M | n/a | 92.0% | -404 | NOK 292.03M | NOK 942.00K | NOK 299.18M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | NOK 380.67M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 NOK.
About Oncoinvent ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Oncoinvent ASA's market cap?
Oncoinvent ASA's market capitalization is NOK 380.67M.
What does Oncoinvent ASA do?
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.